Ajanta Pharma LimitedQ2 FY27 Results & Financial Update
Ajanta Pharma Limited: Q2 FY27 consolidated results and company financials – revenue ₹1,794.16 Cr, PAT ₹388.14 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Ajanta Pharma price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Ajanta Pharma Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the second quarter of fiscal 2027, Ajanta Pharma posted consolidated revenue from operations of INR 1,794.16 crore, marking an increase of 10.34 percent compared to INR 1,625.96 crore in the previous quarter.
Total income for the quarter reached INR 1,831.55 crore, compared to INR 1,696.86 crore in the preceding quarter, supported by other income and interest receipts.
Profit before tax (PBT) expanded by 19.77 percent sequentially to INR 535.15 crore, up from INR 446.80 crore in the quarter ended June 30, 2026.
Net profit after tax (PAT) for Q2 FY27 stood at INR 388.14 crore, representing a 16.13 percent sequential growth over the INR 334.22 crore reported in Q1 FY27.
Basic and diluted earnings per share (EPS) for the quarter rose to INR 31.07, compared to INR 26.72 in the previous quarter.
Total tax expense for the period was reported at INR 147.01 crore, reflecting the higher taxable income base during the quarter.
Finance costs remained minimal at INR 2.24 crore, while depreciation and amortisation expenses were recorded at INR 47.56 crore.
01 · Business model
What does Ajanta Pharma do?
Ajanta Pharma Limited is a specialty pharmaceutical formulation company engaged in developing, manufacturing, and marketing branded and generic pharmaceuticals across global markets.
The company's commercial operations span domestic and international markets, focusing on specialty therapeutic segments such as cardiology, ophthalmology, dermatology, and pain management.
Ajanta operates its own research and development facilities alongside dedicated manufacturing plants, allowing it to maintain end-to-end control over product development and regulatory compliance.
The economic model relies on portfolio differentiation in branded generics and institutional segments, backed by continuous geographic expansion and manufacturing efficiency.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹1,794.16 Cr | ₹1,625.96 Cr |
| Total income | ₹1,831.55 Cr | ₹1,696.86 Cr |
| Profit before tax | ₹535.15 Cr | ₹446.80 Cr |
| Profit after tax | ₹388.14 Cr | ₹334.22 Cr |
| EPS | ₹31.07 | ₹26.72 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 21.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 29.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹37.39 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations increased by 10.34 percent sequentially to INR 1,794.16 crore, driven by expanded realization across active markets.
Total income reached INR 1,831.55 crore, incorporating other income of INR 37.39 crore and interest income of INR 35.93 crore.
What drove margins
PAT margin improved by approximately 108 basis points sequentially, moving from 20.56 percent in Q1 FY27 to 21.63 percent in Q2 FY27.
Depreciation stood at INR 47.56 crore and finance costs remained modest at INR 2.24 crore, supporting net profitability conversion.
04 · Reported developments
What changed operationally
The company recorded double-digit sequential growth in revenue (10.34 percent) and PAT (16.13 percent) over the preceding quarter.
05 · Items worth noticing
The line items that can distort a quick read
The company reported provisions amounting to INR 32.38 crore during the quarter.
Other income was reported at INR 37.39 crore, which includes interest income of INR 35.93 crore.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
XBRL Filing Disclosure
The financial results were submitted via the official exchange integrated XBRL filing portal with un-audited consolidated scope for the quarter ended September 30, 2026.
07 · Previous-quarter changes
What changed since the previous quarter
Revenue grew from INR 1,625.96 crore in Q1 FY27 to INR 1,794.16 crore in Q2 FY27.
PAT expanded from INR 334.22 crore in Q1 FY27 to INR 388.14 crore in Q2 FY27.
08 · Key Q&A
The quarter, answered directly
What does Ajanta Pharma do?
Ajanta Pharma Limited is a specialty pharmaceutical formulation company engaged in developing, manufacturing, and marketing branded and generic pharmaceuticals across global markets.
What is the clearest takeaway from Q2 FY27?
During the second quarter of fiscal 2027, Ajanta Pharma posted consolidated revenue from operations of INR 1,794.16 crore, marking an increase of 10.34 percent compared to INR 1,625.96 crore in the previous quarter.
What drove revenue or demand?
Revenue from operations increased by 10.34 percent sequentially to INR 1,794.16 crore, driven by expanded realization across active markets.
What mattered most for margins or profitability?
PAT margin improved by approximately 108 basis points sequentially, moving from 20.56 percent in Q1 FY27 to 21.63 percent in Q2 FY27.
What changed operationally beyond the headline numbers?
The financial results were submitted via the official exchange integrated XBRL filing portal with un-audited consolidated scope for the quarter ended September 30, 2026.
What should the next disclosure help confirm?
Observe whether the company maintains its improved PAT margin above the 21 percent threshold in subsequent quarters.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Sustained Margin Trajectory: Observe whether the company maintains its improved PAT margin above the 21 percent threshold in subsequent quarters.
- 02
Upcoming Financial Disclosures: Track subsequent quarterly filings for performance comparison against historical benchmarks.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.